NCT05243550Phase 3Active not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Study sponsor: UroGen Pharma Ltd. · URGN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-04-26Actual
Enrollment · participants240Actual
Source updated2026-05-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview